10-Q: Milestone Scientific Reports Q1 2025 Results: Revenue Stable, Losses Widen Amid Cost Increases

Milestone Scientific's Q1 2025 results show stable revenue but increased operating losses due to higher expenses, with management focusing on revenue growth and cost reduction.

Summary

• Milestone Scientific reported a net loss of $1.99 million for Q1 2025, compared to a net loss of $1.44 million for Q1 2024.
• Revenue remained relatively stable at $2.23 million in Q1 2025, slightly down from $2.25 million in Q1 2024.
• The company's operating loss increased to $2.0 million from $1.5 million year-over-year.
• Selling, general, and administrative expenses rose to $3.26 million from $3.04 million.
• Research and development expenses significantly increased to $369,000 from $94,000.
• As of March 31, 2025, Milestone Scientific had cash and cash equivalents of $2.2 million and working capital of $4.2 million.
• Management plans to increase revenues, decrease professional and consulting fees, and delay research and development on the Single Tooth Anesthesia System next generation instrument.
• In April 2025, the company issued promissory notes for $800,000 to related parties to fund operations.
• The company's management believes that existing cash, management plans, and related party note financing will be sufficient to fund operations for the next twelve months.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While revenue is stable, the widening losses and dependence on related party financing raise concerns. The company's ability to continue as a going concern is also a significant risk.

Positives

• Medical revenue increased to approximately $51,000 in Q1 2025, up from $7,400 in Q1 2024.
• The company is actively pursuing positive cash flows through increased dental revenue, medical device revenue, and reduced operating expenses.
• Management believes existing cash, management plans, and related party note financing will be sufficient to fund operations for the next twelve months.
• The company launched an E-Commerce platform selling and shipping STA Single Tooth Anesthesia System (STA) and handpieces directly to dental offices and dental groups within the U.S.

Negatives

• The company's operating losses were approximately $2.0 million for the three months ended March 31 2025.
• The company has incurred total losses since inception of $130.0 million.
• The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.
• The company has decided to delay research and development on the STA Single Tooth Anesthesia System next generation instrument.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital and achieving profitability.
• The termination of manufacturing relationships with third-party manufacturers could adversely affect the company's ability to produce and sell its products.
• Changes to United States tariff and import/export regulations may have a material adverse effect on the company's business, financial condition and results of operations.
• Government action on tariffs and research grants and other funding may impede the company's ability to conduct its research and to raise capital.
• The company has a purchase commitment for the delivery of 2,200 STA instruments as of March 31, 2025.

Future Outlook

Management plans to increase revenues, decrease professional and consulting fees, and delay research and development on the Single Tooth Anesthesia System next generation instrument. The company believes that the existing cash and cash equivalents along with management plans, and the $800,000 in related party note financing received in April 2025 will be sufficient to enable the Company to fund operations for the twelve months from the issuance of these financial statements and alleviates substantial doubt about the Company's ability to continue as a going concern.

Management Comments

• Management has developed and is implementing plans to increase revenues and decrease professional and consulting fees over the next twelve months.
• The Company has also decided to delay all research and development on the Single Tooth Anesthesia System next generation instrument.
• The Company believes that the existing cash and cash equivalents along with management plans, and the $800,000 in related party note financing received in April 2025 will be sufficient to enable the Company to fund operations for the twelve months from the issuance of these financial statements and alleviates substantial doubt about the Company's ability to continue as a going concern.

Industry Context

Milestone Scientific operates in the biomedical technology industry, focusing on innovative injection technologies. The company faces competition from established players in the dental and medical device markets. The company's success depends on the adoption of its products by healthcare professionals and the ability to secure reimbursement for procedures using its devices.

Comparison to Industry Standards

• It is difficult to compare Milestone Scientific directly to industry standards due to its unique product offerings and small size compared to larger medical and dental device companies.
• Companies like Dentsply Sirona and Danaher Corporation in the dental space, and Medtronic and Johnson & Johnson in the medical device space, have significantly larger revenue bases and broader product portfolios.
• Milestone Scientific's focus on computer-controlled injection technology differentiates it, but also requires it to educate the market and overcome potential resistance to new technologies.
• The company's ability to secure CPT codes and reimbursement for its CompuFlo Epidural System is crucial for its success in the pain management market, as reimbursement is a key driver of adoption for medical devices.

Related Party Transactions

• The company issued a series of promissory notes in the aggregate amount of $800,000 to Mr. Neal Goldman, Ms. Benedetta Casamento, and Dr. Didier Demesmin, each of whom is a director of the Company.
• Milestone Scientific has a supply agreement with United Systems, the principal supplier of its handpieces.
• The Director of Clinical Affairs royalty fee was approximately $112,000 for the three months ended March 31, 2025.
• The Company entered into a consulting agreement with Mr. Arjan Haverhals.

Stakeholder Impact

• Shareholders face the risk of dilution from potential equity offerings and the conversion of promissory notes.
• Employees may be affected by cost-cutting measures and potential delays in research and development projects.
• Customers may benefit from the company's innovative products, but also face the risk of supply disruptions if manufacturing relationships are terminated.
• Suppliers may be impacted by changes in the company's purchasing patterns and potential financial difficulties.
• Creditors face the risk of non-payment if the company is unable to raise additional capital or achieve profitability.

Next Steps

• Increase revenue from dental business worldwide.
• Generate revenue from medical devices and disposables business in the United States and worldwide.
• Reduce operating expenses.
• Continue to expand the uses and applications of our DPS Dynamic Pressure Sensing technology.

Key Dates

Keywords

Milestone Scientific, financial results, Q1 2025, revenue, net loss, operating expenses, cash flow, going concern, STA System, CompuFlo, epidural, dental, medical, related party transactions